If you are talking about Polycythemia vera (PV), which is clonal, neoplastic myeloproliferative disease, the risk of progression towards post PV myelofibrosis and secondary acute myeloid leukemia (sAML) is well recognized. You will find a lot of literature on the subject. Below, a short list of relevant publications.
Approximately 10% of patients develop “post-PV myelofibrosis” (PPMF), an unfortunate appellation conjuring comparison with PMF, however, PPMF behaves differently. Marrow reticulin fibrosis is a reactive, reversible histologic process, which does not affect bone marrow function and can be present in PV at diagnosis without impacting survival.
Leukemic transformation, the most serious PV consequence, can develop in chronic phase, but more frequently during PPMF, spontaneously or associated with chemotherapy or irradiation, particularly in patients age ≥60 years. Neither JAK2V617F expression nor its variant allele frequency (VAF) correlate with leukemic transformation, genomic changes, or survival, unless there is mutation homozygosity. Approximately 30% of cases are JAK2V617F-negative, presumably originating in the ancestral LT-HSC clone; recent studies suggest genetic instability is less marked in PPMF than in PMF.
polycythemia can be categorized into absolute and relative type. Absolute polycythemia : increase in total red cell mass which includes both polycythemia vera and secondary polycythemia. Myeloproliferative disorders (MPDs) comprise polycythemia vera (PV), essential thrombocythemia (ET) and idiopatic myelofibrosis (IMF). these disorders share many features including altered stem cell behavior, overproduction of myeloid leukemia lineages and rarely transformation to acute myeloid leukemia (AML).